MIR1275

Summary

MIR1275 (microRNA 1275, HGNC:35346) is a microRNA gene on chromosome 6p21.31.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100302123 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:35346
Approved symbol	MIR1275
Name	microRNA 1275
Location	6p21.31
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-1275
Ensembl gene	ENSG00000221697
Ensembl biotype	miRNA
Entrez	100302123
RNAcentral	URS00006C1415 — miRNA, 80 nt, 3 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000408770

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000408770 — 1 exons

Exon	Start	End
ENSE00001565405	33999972	34000051

Expression profiles

Bgee: expression breadth broad, 32 present calls, max score 82.32.

Top tissues by expression

32 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.32	gold quality
monocyte	CL:0000576	80.34	gold quality
skin of leg	UBERON:0001511	72.34	gold quality
islet of Langerhans	UBERON:0000006	72.32	gold quality
right hemisphere of cerebellum	UBERON:0014890	72.08	gold quality
lung	UBERON:0002048	71.15	gold quality
cerebellar hemisphere	UBERON:0002245	70.86	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	70.77	gold quality
amygdala	UBERON:0001876	70.41	gold quality
gastrocnemius	UBERON:0001388	70.12	gold quality
body of stomach	UBERON:0001161	68.64	gold quality
Ammon’s horn	UBERON:0001954	68.59	gold quality
blood	UBERON:0000178	68.24	gold quality
ascending aorta	UBERON:0001496	67.62	gold quality
Brodmann (1909) area 9	UBERON:0013540	67.61	gold quality
right frontal lobe	UBERON:0002810	67.21	gold quality
transverse colon	UBERON:0001157	65.86	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	65.72	gold quality
putamen	UBERON:0001874	65.31	gold quality
body of uterus	UBERON:0009853	63.93	gold quality
endocervix	UBERON:0000458	63.32	gold quality
skin of abdomen	UBERON:0001416	63.03	gold quality
prostate gland	UBERON:0002367	62.91	gold quality
nucleus accumbens	UBERON:0001882	62.88	gold quality
subcutaneous adipose tissue	UBERON:0002190	62.86	gold quality
caudate nucleus	UBERON:0001873	60.91	gold quality
tibial nerve	UBERON:0001323	58.36	gold quality
spleen	UBERON:0002106	57.51	gold quality
hypothalamus	UBERON:0001898	56.07	gold quality
corpus callosum	UBERON:0002336	44.41	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.33

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 23)

• Treatment with 3-deazaneplanocin A, an inhibitor of H3K27 methyltransferase, attenuated CLDN11 induction by serum stimulation in parallel with sustained miR-1275 expression (PMID:22736761)
• Data show that insulin-like growth factor-2-mRNA-binding proteins IGF2BP1, IGF2BP2, and IGF2BP3 are direct targets of microRNA-1275 (miR-1275). (PMID:26160756)
• we have shown that miR-1275 is a novel negative regulator of human visceral preadipocyte differentiation, which appears to act via post-transcriptional silencing of ELK1. (PMID:27154547)
• Inflammatory factors suppress microRNA-1275 transcription in human adipocytes through NF-kappaB. (PMID:28901460)
• MiR1275 underexpression is associated with myelodysplastic syndrome and acute myeloblastic leukemia. (PMID:29102598)
• Data found that miR-1275 was up-regulated in squamous cell carcinoma of head and neck (SCCHN) tissues and advanced metastatic SCCHN cells. These results report for the first time that miR-1275 could act as a tumor-promoter in SCCHN possibly by regulating its target gene via novel miRNA mechanisms. MiR-1275 plays an important role in promoting SCCHN progression. (PMID:29278769)
• demonstrated that circMAN2B2 acts as an oncogenic role in lung cancer through promoting FOXK1 expression by sponging miR-1275 (PMID:29550475)
• The study demonstrated that HAND2-AS1 exerts a suppressive role in colorectal cancer by sponging miR-1275 and modulating KLF14 expression. (PMID:30078677)
• LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells by sponging with micRNA-1275. (PMID:30915755)
• circMAN2B2 could improve cell proliferation, invasion, and migration of the glioma by inhibiting miR-1205 and promoting the expression of S100A8. (PMID:31131447)
• This study found that the expression of the mature astrocyte marker GFAP is transcriptionally suppressed by miR-1275, which is negatively regulated by cAMP/PKA/PRC2/H3K27me3 signaling. Downregulation of miR-1275 contributes to the glial induction of glioblastoma cells. (PMID:31162799)
• Increased miR-1275 expression inhibited gastric cancer metastasis by regulating vimentin/E-cadherin via direct suppression of JAZF1expression, suggesting that miR-1275 is a tumour-suppressor miRNA with the potential as a prognostic biomarker or therapeutic target in gastric cancer. (PMID:31357957)
• LncRNA HAND2-AS1 sponging miR-1275 restrains proliferation and metastasis of breast cancer cells by regulating SOX7 expression. (PMID:31683462)
• MicroRNA-1275 induces radiosensitization in oesophageal cancer by regulating epithelial-to-mesenchymal transition via Wnt/beta-catenin pathway. (PMID:31733028)
• Long non-coding RNA DANCR induces chondrogenesis by regulating the miR-1275/MMP-13 axis in synovial fluid-derived mesenchymal stem cells. (PMID:31841200)
• Blood miR-1275 levels were negatively associated with the occurrence of Ischemic stroke (IS), and miR-1275 might exert an athero-protective role against the development of IS by targeting ApoC2 and blocking the formation of macrophage foam cells. (PMID:31935511)
• Interaction analysis of miR-1275/IGF2BP1/IGF2BP3 with the susceptibility to hepatocellular carcinoma. (PMID:32134323)
• Knockdown of miR-1275 protects against cardiomyocytes injury through promoting neuromedin U type 1 receptor. (PMID:33323026)
• Dysregulation of the miR-1275/HK2 Axis Contributes to the Progression of Hypoxia/Reoxygenation-Induced Myocardial Injury. (PMID:33551225)
• MACE-Seq-based coding RNA and TrueQuant-based small RNA profile in breast cancer: tumor-suppressive miRNA-1275 identified as a novel marker. (PMID:33910530)
• miR-1275 Inhibits Human Omental Adipose-Derived Stem Cells Differentiation Toward the Beige Phenotype via PRDM16. (PMID:36128801)
• miR-1275 targets MDK/AKT signaling to inhibit breast cancer chemoresistance by lessening the properties of cancer stem cells. (PMID:36594100)
• Circ_0002715 promotes the development of osteoarthritis through regulating LXN by sponging miR-127-5p. (PMID:36949500)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.